CN107998252A - It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application - Google Patents
It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application Download PDFInfo
- Publication number
- CN107998252A CN107998252A CN201711329490.XA CN201711329490A CN107998252A CN 107998252 A CN107998252 A CN 107998252A CN 201711329490 A CN201711329490 A CN 201711329490A CN 107998252 A CN107998252 A CN 107998252A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- pharmaceutical composition
- pharmaceutical chemicals
- bulk pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 38
- 239000000126 substance Substances 0.000 claims abstract description 30
- 241001148782 Davallia Species 0.000 claims abstract description 21
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 20
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 20
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 20
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 20
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 20
- 241000123589 Dipsacus Species 0.000 claims abstract description 20
- 239000004863 Frankincense Substances 0.000 claims abstract description 20
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 20
- 239000009136 dragon's blood Substances 0.000 claims abstract description 20
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241001465251 Ephedra sinica Species 0.000 claims abstract description 19
- 229910052802 copper Inorganic materials 0.000 claims abstract description 19
- 239000010949 copper Substances 0.000 claims abstract description 19
- 241001043298 Croton draco Species 0.000 claims abstract 5
- 208000010392 Bone Fractures Diseases 0.000 claims description 30
- 206010017076 Fracture Diseases 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 18
- 239000012467 final product Substances 0.000 claims description 16
- 239000006187 pill Substances 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- -1 decoction Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 241000131329 Carabidae Species 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 4
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 240000004824 Trimezia steyermarkii Species 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000212321 Levisticum Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000005214 Poroma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000001013 eccrine acrospiroma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition, it is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：25 55 parts of frankincense, 30 55 parts of myrrh, 25 50 parts of dragon's blood, 15 45 parts of teasel root, 20 40 parts of the rhizome of davallia, 15 40 parts of ground bettle, 8 22 parts of native copper, 6 20 parts of Chinese ephedra.Present invention also offers the preparation method and purposes of the pharmaceutical composition.Pharmaceutical composition compatibility of the present invention is precise and appropriate, and each taste medicine complements each other, and has no adverse reaction, and energy rapid pain relief, accelerates patient and get well, significantly shorten the healing time of fracture or bone split, can effectively treat fracture or bone split, have stronger actual application value.
Description
Technical field
Fracture or the pharmaceutical composition of bone split are treated the present invention relates to a kind of.
Background technology
Fracture is that the continuity of bone structure is broken completely or partially.Be more common in children and the elderly, young people also when
There is generation.Patient is often-a position fracture, and minority is multiple fracture.Through appropriate processing in time, most patients can recover former
The function of coming, a few patients can leave different degrees of sequelae.
At present clinically for fracture based on operative treatment, by open reset or internal fixation with steel plate pair is used
Fracture portions are treated.However, operative treatment fracture but faces the drawbacks such as high cost, wound are big, complication is more, for example,
Operation can damage periosteum and surrounding soft tissue, influence local blood and supply, extension healing time, and metal inside-fixture
Can occur rejection, and it is possible that postoperative unknown cause hyperpyrexia, the enhancing of fracture periosteal reaction, occur nail trace,
Bone ischemic, bone information and poroma delay the complication such as moulding, and the prognosis to patient causes harmful effect.
Orthopedics of Chinese Medicine developing history it is long, show according to clinical research, traditional Chinese medical science conservative treatment can effectively treat fracture,
There is the characteristics of spending less, wound is small, good prognosis compared to operative treatment, be not only able to the recovery of promotion patient health also significantly
The time for shortening union.Chen little Jun, " limbs fracture tcm characteristic therapeutic effect ", Clinical Journal of
Chinese Medicine, the 18th phase in 2012 disclose oral Thyroid Nodules (radix astragali 30g, Radix Salviae Miltiorrhizae 20g, HERBA EPIMEDII
20g, Ligusticum wallichii 20g, dipsacus root 20g, Angelica sinensis 15g, Fructus Corni 15g, calcined Dragon's bone 15g, cultivated land 15g, Chinese yam 15g, safflower 20g, the radix paeoniae rubrathe
12g, Semen Cuscutae 12g, rhizome of davallia 12g, cortex albiziae 12g, radix glycyrrhizae 6g), and coordinate manipulative reduction, plintlet to fix and the external application of Chinese medicine
Fracture can effectively be treated.Application number：96103489.0 denomination of invention：A kind of medicine for treating fracture and long bone patch, it mainly with
Notopterygium root, levisticum, frankincense, myrrh, the rhizome of davallia, pyritum ignited, orange peel, dragon's blood, Soil unit are prepared, which is externally applied drug,
By the way that bulk pharmaceutical chemicals are pulverized, stir evenly and spread on affected part, fracture can be treated.
Now have no to coordinate frankincense, myrrh, dragon's blood, teasel root, the rhizome of davallia, ground bettle, native copper and Chinese ephedra and be used to treat bone
Folding or the report of bone split.
The content of the invention
Fracture or the pharmaceutical composition of bone split are treated the present invention provides a kind of, and its preparation method and application.
The present invention provides a kind of pharmaceutical composition, it is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：
25-55 parts of frankincense, 30-55 parts of myrrh, 25-50 parts of dragon's blood, 15-45 parts of teasel root, 20-40 parts of the rhizome of davallia, 15-40 parts of ground bettle,
8-22 parts of native copper, 6-20 parts of Chinese ephedra.
Wherein, it is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：30-50 parts of frankincense, myrrh 35-50
Part, 30-45 parts of dragon's blood, 20-40 parts of teasel root, 25-35 parts of the rhizome of davallia, 20-35 parts of ground bettle, 10-20 parts of native copper, Chinese ephedra 8-18
Part.
Wherein, it is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：40 parts of frankincense, 40 parts of myrrh, dragon's blood
40 parts, 30 parts of teasel root, 30 parts of the rhizome of davallia, 30 parts of ground bettle, 15 parts of native copper, 15 parts of Chinese ephedra.
Wherein, the composition is with frankincense, myrrh, dragon's blood, teasel root, the rhizome of davallia, ground bettle, native copper and the medicine of Chinese ephedra
Powder, or water or extractive with organic solvent are active ingredient, are prepared into plus pharmaceutically acceptable auxiliary material pharmaceutically common
Preparation.
Pharmaceutically acceptable auxiliary material of the present invention, refers to the material being included in addition to the active ingredient (s in formulation, bag
Include but be not limited only to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, adjusting
Agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc..Adhesive include syrup, Arabic gum, gelatin, sorbierite,
Tragacanth, cellulose and its derivates (such as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or hydroxypropyl methylcellulose
Element etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.；Filler include lactose, Icing Sugar, dextrin, starch and its
Derivative, cellulose and its derivates, inorganic calcium salt (such as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate), sorb
Alcohol or glycine etc.；Lubricant includes superfine silica gel powder, magnesium stearate, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, poly- second
Glycol etc.；Disintegrant includes starch and its derivative (such as sodium carboxymethyl starch, Explotab, pregelatinized starch, improvement shallow lake
Powder, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.；Wetting agent includes dodecyl sulphate
Sodium, water or alcohol etc.；Antioxidant packages are containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.；Bacteriostatic agent includes
0.5% phenol, 0.3% cresols, 0.5% anesin etc.；Conditioning agent includes hydrochloric acid, citric acid, potassium hydroxide (sodium), citron
Sour sodium and buffer (including sodium dihydrogen phosphate and disodium hydrogen phosphate) etc.；Emulsifying agent includes Tween-80, aliphatic acid sorb
Smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.；Solubilizer includes Tween-80, bile, glycerine etc..
The pharmaceutically acceptable complementary component, it has certain physiological activity, but the addition of the component will not change
Become the leading position of above-claimed cpd or derivative in treatment of diseases, and only play auxiliary effect, these auxiliary work(
Effect is only the utilization to the component known activity, is the usual adjuvant treatment modality of field of medicaments.If by it is above-mentioned it is complementary into
Divide and be used cooperatively with the compounds of this invention, still should belong to the scope of protection of the invention.
Wherein, the preparation is oral formulations.
Wherein, the preparation is powder, decoction, granule, tablet, capsule, oral liquid, pill.
The present invention also extracts the preparation method of foregoing pharmaceutical composition, it is comprised the following steps：
(1) bulk pharmaceutical chemicals of each weight proportion are weighed；
(2) bulk pharmaceutical chemicals directly beat powder, or bulk pharmaceutical chemicals are added water to cook or organic solvent extracts, and extracting solution concentration, adds
Pharmaceutically acceptable auxiliary material or complementary component are prepared into pharmaceutically common preparation.
Water extract is used as medicine with medicinal powder, is Chinese medicine tradition occupation mode, after water carries, since the soluble end of water is wide, and energy
Enough by most of active ingredient dissolution, make medicine be easier to be absorbed by the body, work faster, such as the form of medication such as decoction；With
Original powder is used as medicine, and the surface area of medicinal powder is larger, is also beneficial to the absorption of active ingredient in vivo in medicinal material, but medicinal material is un-extracted,
Active ingredient still needs to the re-absorption of dissolution in vivo, its opposite water extract that works is slower, but also weakens and be harmful into medicinal material at the same time
Divide the toxicity caused by human body, be suitable for long-term use, original powder is such as prepared into pill form of medication.At present in pharmacy
During, ethanol extracts medicine as solvent, and one of most commonly seen extracting mode, and ethanol is molten for semi-polarity
Agent, solubility property circle can dissolve water miscible some components between polarity and nonpolar solvent, can also dissolve nonpolar molten
Some components of agent dissolving, usually replace decocting with ethanol extraction, so as to avoid the dissolution of a large amount of invalid components, raising effectively into
The concentration and extraction efficiency divided, but the price of ethanol is expensive compared with water, in the big production of modern pharmaceutical industry, is produced into save
This, usually or based on decocting.In the case where the water extract of known compositions of the present invention has physiological activity, in order to adapt to
Various productions and demand when using, can optionally water carries, original powder, alcohol extracting or combinations thereof method prepare specific agent
Type.
Wherein, specific preparation method is as follows：
Decoction：Bulk pharmaceutical chemicals are weighed, are decocted, filtering, to obtain the final product；
Powder：Weigh bulk pharmaceutical chemicals, beat powder, sieve, to obtain the final product；
Granule：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate concentration, dry, addition auxiliary material or auxiliary
Helping property component, mixes, granulation, whole grain, drying, to obtain the final product；
Tablet：Weigh bulk pharmaceutical chemicals, add water or organic solvent to extract, filtering, filtrate concentration, add auxiliary material or it is complementary into
Point, granulation, whole grain, tabletting, to obtain the final product；
Capsule：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate is concentrated and dried, and adds auxiliary material or auxiliary
Property component, mix, it is encapsulated, to obtain the final product；
The water-bindered pill：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add excipient, water pill is dry, to obtain the final product；
Honeyed bolus：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add honey, pill is dry, to obtain the final product；
Dripping pill：Bulk pharmaceutical chemicals are weighed, adds water or organic solvent to extract, filters, matrix is added in filtrate, mix heating and melting,
Instill in not miscible condensate liquid and condense, to obtain the final product.
The organic solvent is the ethanol of various concentrations, such as the ethanol of 25%-95%.
The present invention finally provides purposes of the foregoing pharmaceutical composition in the medicine for the treatment of fracture or bone split is prepared.
Ancient Times in China ancient books and records have description to the treatment after fracture and prognosis.《Plain Questions menstruation regulating opinion》Cloud：" owner of people,
Blood and gas ear ".《It is difficult difficult through 22》Cloud：" qi warming body, blood nourishing.”《A Ling Shu Miraculous Pivot or Divine Axis passages through which vital energy circulates pieces》Cloud：" part of the body cavity above the diaphragm housing the heart and lungs outlet, with
Warm boundary between muscles and nourishing the bone section ".《This Tibetan of Ling Shu Miraculous Pivot or Divine Axis piece》Cloud：" passages through which vital energy circulates person, so qi and blood circulation promotion and Rong Yinyang, moisten muscles and bones, sharp joint person
".Above ancient books describes out the material base that qi and blood is physical activity, and bone be unable to do without supplementing nutrition for qi and blood；When passages through which vital energy circulates is unimpeded, gas
Blood reconciles, and bone supplements nutrition with regard to that can obtain and makes powerful muscle and bone.《General Records of Holy Universal Relief traumatics fracture door》Cloud：" people all over the body, defend by blood Ying Qi, circulates
It is infinite, or muscles joint, cause to be traumaticd fracture by mistake, then qi and blood stasis pain, must not hinder, and must not roll over and continues "." arteries and veins person's house of blood,
In blood arteries and veins, pass through and managed in meat, ring Zhou Yishen, because solid outside its human body, leads in passages through which vital energy circulates, be can streamer not lose its normal.It is if interior because traumatiing fracture
Dynamic channels and collaterals, the road of blood must not declare logical, and siltation does not dissipate, and is pain to swell, and controls and preferably removes evil silt, makes qi and blood circulation, then can be complete again
." Chen Shiduo《The dialectical record of all kinds of diseases and ailments》Cloud：" blood not reviver become silted up do not go, silt do not go then bone cannot connect." it can be seen from the above, fracture
After, it is necessary to passages through which vital energy circulates is unimpeded, and qi and blood, which reconciles, to heal；If qi depression to blood stasis, passages through which vital energy circulates occlusion, then derangement of Qi and blood, the broken ends of fractured bone obtain not
To nourishing, just it is difficult to heal.In addition,《Plain Questions declares a five gas pieces》Cloud：" Shen controls bone "；《The big opinion of YIN YANG classification of natural phenomena》Cloud：" kidney gives birth to bone
Marrow "；《Six sections are hidden as opinion》Also say：" kidney person, it is filled in bone ".The vital essence of kidney is explicitly pointed out, bone can be given birth to and brought up.Kidney qi is vigorous then
Bone growth, then bone also fails therewith for kidney qi decline.
It is considered herein that fracture or the interpretation of the cause, onset and process of an illness of bone split are deficiency of kidney-QI, vim and vigour are got along well, and muscles and bones is weak；To proceed blood cycle, mend
Kidney-nourishing essence is treatment fracture or the mechanism of bone split, can nourish kidney qi, the regulation of qi and blood, to achieve the purpose that to give birth to and bring up bone, so as to have
Effect treatment fracture or bone split.
In pharmaceutical composition of the present invention, frankincense, myrrh are monarch drug in a prescription, and blood-activating and qi-promoting relieves pain, detumescence and promoting granulation；Dragon's blood is ministerial drug,
Promoting blood circulation analgesic therapy, removing blood stasis and hemostasis, expelling pus and promoting granulation；Assistant is with teasel root, the rhizome of davallia, ground bettle, The strong bone of kidney tonifying, dissipating blood stasis with potent drugs, reunion of fractured tendons and bones；
Again using native copper and Chinese ephedra to make coordinating the drug actions of a prescription and priming power downlink.
Pharmaceutical composition compatibility of the present invention is precise and appropriate, and each taste medicine complements each other, and has no adverse reaction, and energy rapid pain relief, adds
Fast patient gets well, and significantly shortens the healing time of fracture or bone split, can effectively treat fracture or bone split, have stronger reality
Border application value.
Obviously, the above according to the present invention, according to the ordinary technical knowledge and customary means of this area, is not departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The embodiment of form by the following examples, remakes further specifically the above of the present invention
It is bright.But the scope that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to following example.It is all to be based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Embodiment
The preparation of 1 medicinal tablet of the present invention of embodiment
Take frankincense 40g, myrrh 40g, dragon's blood 40g, teasel root 30g, rhizome of davallia 30g, ground bettle 30g, native copper 15g, Chinese ephedra
15g, beats powder, direct powder compression, up to tablet.
The preparation of 2 medicinal tablet of the present invention of embodiment
Take frankincense 25g, myrrh 30g, dragon's blood 25g, teasel root 15g, rhizome of davallia 20g, ground bettle 15g, native copper 8g, Chinese ephedra
6g, adds water to cook extraction, is condensed into medicinal extract, starch granulation, whole grain, tabletting is added, up to tablet.
The preparation of 3 medicine capsule of the present invention of embodiment
Take frankincense 55g, myrrh 55g, dragon's blood 50g, teasel root 45g, rhizome of davallia 40g, ground bettle 40g, native copper 22g, Chinese ephedra
20g, adds water to cook extraction, is condensed into medicinal extract, adds auxiliary material, mixes, packing, up to capsule.
The preparation of the medicine water-bindered pill of the present invention of embodiment 4
Take frankincense 30g, myrrh 35g, dragon's blood 30g, teasel root 20g, rhizome of davallia 25g, ground bettle 20g, native copper 10g, Chinese ephedra
8g, beats powder, sieving, adds excipient, water pill is dry, up to the water-bindered pill.
The preparation of the medicine honeyed bolus of the present invention of embodiment 5
Take frankincense 50g, myrrh 50g, dragon's blood 45g, teasel root 40g, rhizome of davallia 35g, ground bettle 35g, native copper 20g, Chinese ephedra
18g, beats powder, sieving, adds honey, pill is dry, up to honeyed bolus.
The preparation of the medicine decoction of the present invention of embodiment 6
Take frankincense 40g, myrrh 40g, dragon's blood 40g, teasel root 30g, rhizome of davallia 30g, ground bettle 30g, native copper 15g, Chinese ephedra
15g, soaks decoction, merging filtrate, filtering, up to decoction.
The preparation of 7 medicinal tablet of the present invention of embodiment
Take frankincense 50g, myrrh 50g, dragon's blood 45g, teasel root 40g, rhizome of davallia 35g, ground bettle 35g, native copper 20g, Chinese ephedra
18g, is extracted with ethanol, obtains ethanol extract, is condensed into medicinal extract, starch granulation, whole grain, tabletting is added, up to tablet.
The preparation of 8 medicine oral liquid of the present invention of embodiment
Take frankincense 30g, myrrh 35g, dragon's blood 30g, teasel root 20g, rhizome of davallia 25g, ground bettle 20g, native copper 10g, Chinese ephedra
8g, soaks decoction, merging filtrate, concentration, embedding, sterilizing, up to oral liquid.
Beneficial effects of the present invention are proved below by way of specific clinical test：
1 medicine composite for curing of the present invention of test example is fractured or the clinical efficacy of bone split
1 experiment material
1.1 experimental drugs pharmaceutical composition of the present invention, is prepared by embodiment 1.
1.2 patient datas observe case totally 49, and the age is 38 years old average.
2 experimental methods
2.1 include case standard：1. it is diagnosed as the patient of fracture.2. it is diagnosed as the patient of bone split.
2.2 Excluded cases standards：1. pregnant woman, those who are allergic to this drug.2. it is associated with angiocarpy, liver, kidney and hemopoietic system etc.
Severe primary disease, mental patient.3. all do not meet inclusive criteria, not by regulation medication, curative effect or data can not be judged
It is not congruent to affect the treatment or security judgement person.
2.3 curative effects judge
Cure：Joint structure is normal, and symptom disappears, and function is wholly or substantially recovered.
Improve：Joint structure is normal, and symptom improves, and funtion part is limited.
It is not cured：Dislocation does not reset, and symptom is without improvement, dysfunction.
2.4 medication
Daily 3 times, early, middle and late once a dose, each taking when need to separate more than half an hour with the meal time,
Each taking medicine equivalent to 3 grams crude drugs of weight, and need to be taken with yellow rice wine or red wine, to help the efficacy of a drug.
3 experimental results
The experiment results show that 1 month visible positive effect is taken, and pharmaceutical composition of the present invention, total effective rate 100%, this
Invention pharmaceutical composition can effectively treat fracture or bone split.
2 medicine composite for curing of the present invention of test example is fractured or the model case of bone split
Case one：5 XX, man 38 years old, sprain waist, cause Section of three lumbar vertebrae bone split, lie up when playing bowling, take
Considerably reduced with 2 days feeling of pains after this medicine, slow walking of leaving the bed after 33 days, check affected part of being admitted to hospital for 40 days is healed completely.
Case two：Lee X, man 16 years old, is sprained accidentally when school moves, and admission examination is left foot anklebone bone split, takes this
Fully recover within 20 days after medicine.
To sum up, pharmaceutical composition compatibility of the present invention is precise and appropriate, and each taste medicine complements each other, and has no adverse reaction, and can alleviate pain rapidly
Bitterly, accelerate patient get well, significantly shorten fracture or bone split healing time, can effectively treat fracture or bone split, have compared with
Strong actual application value.
Claims (9)
- A kind of 1. pharmaceutical composition, it is characterised in that：It is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：Frankincense 25-55 parts, it is 30-55 parts of myrrh, 25-50 parts of dragon's blood, 15-45 parts of teasel root, 20-40 parts of the rhizome of davallia, 15-40 parts of ground bettle, natural 8-22 parts of copper, 6-20 parts of Chinese ephedra.
- 2. pharmaceutical composition according to claim 1, it is characterised in that：It is prepared by the bulk pharmaceutical chemicals of following weight proportioning The preparation formed：30-50 parts of frankincense, 35-50 parts of myrrh, 30-45 parts of dragon's blood, 20-40 parts of teasel root, 25-35 parts of the rhizome of davallia, ground beetle 20-35 parts of worm, 10-20 parts of native copper, 8-18 parts of Chinese ephedra.
- 3. pharmaceutical composition according to claim 2, it is characterised in that：It is prepared by the bulk pharmaceutical chemicals of following weight proportioning The preparation formed：40 parts of frankincense, 40 parts of myrrh, 40 parts of dragon's blood, 30 parts of teasel root, 30 parts of the rhizome of davallia, 30 parts of ground bettle, native copper 15 Part, 15 parts of Chinese ephedra.
- 4. according to the pharmaceutical composition described in claim 1-3 any one, it is characterised in that：The composition be with frankincense, Myrrh, dragon's blood, teasel root, the rhizome of davallia, ground bettle, native copper and the medicinal powder of Chinese ephedra, or water or extractive with organic solvent are effective Component, pharmaceutically common preparation is prepared into plus pharmaceutically acceptable auxiliary material.
- 5. pharmaceutical composition according to claim 4, it is characterised in that：The preparation is oral formulations.
- 6. pharmaceutical composition according to claim 5, it is characterised in that：The preparation is powder, decoction, granule, piece Agent, capsule, oral liquid, pill.
- 7. the preparation method of the pharmaceutical composition described in claim 1-6 any one, it is characterised in that：It includes following step Suddenly：(1) bulk pharmaceutical chemicals of each weight proportion are weighed；(2) bulk pharmaceutical chemicals directly beat powder, or bulk pharmaceutical chemicals are added water to cook or organic solvent extracts, and extracting solution concentration, adds pharmacy Upper acceptable auxiliary material or complementary component are prepared into pharmaceutically common preparation.
- 8. preparation method according to claim 7, it is characterised in that：Specific preparation method is as follows：Decoction：Bulk pharmaceutical chemicals are weighed, are decocted, filtering, to obtain the final product；Powder：Weigh bulk pharmaceutical chemicals, beat powder, sieve, to obtain the final product；Granule：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate concentration, dry, addition auxiliary material or complementary Component, mixes, granulation, whole grain, drying, to obtain the final product；Tablet：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate concentration, add auxiliary material or complementary component, system Grain, whole grain, tabletting, to obtain the final product；Capsule：Weigh bulk pharmaceutical chemicals, add water or organic solvent to extract, filtering, filtrate is concentrated and dried, add auxiliary material or it is complementary into Point, mix, it is encapsulated, to obtain the final product；The water-bindered pill：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add excipient, water pill is dry, to obtain the final product；Honeyed bolus：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add honey, pill is dry, to obtain the final product；Dripping pill：Bulk pharmaceutical chemicals are weighed, adds water or organic solvent to extract, filters, matrix is added in filtrate, mix heating and melting, instill Condensed in not miscible condensate liquid, to obtain the final product.
- 9. purposes of the pharmaceutical composition in the medicine for the treatment of fracture or bone split is prepared described in claim 1-6 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711329490.XA CN107998252A (en) | 2017-12-13 | 2017-12-13 | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711329490.XA CN107998252A (en) | 2017-12-13 | 2017-12-13 | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107998252A true CN107998252A (en) | 2018-05-08 |
Family
ID=62058620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711329490.XA Pending CN107998252A (en) | 2017-12-13 | 2017-12-13 | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107998252A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209764A (en) * | 2022-01-14 | 2022-03-22 | 包头云龙骨科医院有限责任公司 | Pharmaceutical composition for treating bone fracture, preparation and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125608A (en) * | 1995-05-19 | 1996-07-03 | 张治国 | Patent drug- "jiegu" powder medicine for treatment of fracture |
| CN1593583A (en) * | 2004-06-18 | 2005-03-16 | 南京中医药大学 | Compound preparation for bone fracture and its preparation method |
| CN1660179A (en) * | 2004-12-24 | 2005-08-31 | 朱维俊 | Chinese traditional medicine for treating fracture of senior citizens |
-
2017
- 2017-12-13 CN CN201711329490.XA patent/CN107998252A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125608A (en) * | 1995-05-19 | 1996-07-03 | 张治国 | Patent drug- "jiegu" powder medicine for treatment of fracture |
| CN1593583A (en) * | 2004-06-18 | 2005-03-16 | 南京中医药大学 | Compound preparation for bone fracture and its preparation method |
| CN1660179A (en) * | 2004-12-24 | 2005-08-31 | 朱维俊 | Chinese traditional medicine for treating fracture of senior citizens |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209764A (en) * | 2022-01-14 | 2022-03-22 | 包头云龙骨科医院有限责任公司 | Pharmaceutical composition for treating bone fracture, preparation and application |
| CN114209764B (en) * | 2022-01-14 | 2023-08-29 | 包头云龙骨科医院有限责任公司 | Pharmaceutical composition, preparation and application for treating fracture |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN101810763B (en) | Chinese medicinal preparation for curing male infertility and sexual dysfunction and preparation method thereof | |
| CN104940810A (en) | Traditional Chinese medicine composition for treating angina | |
| CN1109554C (en) | Medicine for treating allergic purpura | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN108159125A (en) | A kind of external medicine composition and its preparation method and application of expelling wind and clearing away cold, promoting blood circulation and stopping pain | |
| CN107998252A (en) | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application | |
| CN104548049A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN108126077A (en) | A kind of pharmaceutical composition for treating fracture or bone split and its preparation method and application | |
| CN103520450A (en) | Traditional Chinese medicine treating postpartum rheumatism | |
| CN103330837A (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN106511549A (en) | Traditional Chinese medicine composition containing millettia specisoa and preparation method of traditional Chinese medicine composition | |
| CN108014237A (en) | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application | |
| CN105213758A (en) | A kind of Chinese medicine composition for the treatment of chronic pneumonia and preparation method thereof | |
| CN106860717A (en) | It is a kind of to treat infertile medicine | |
| CN108014235A (en) | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application | |
| CN107998253A (en) | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application | |
| CN108042679A (en) | A kind of pharmaceutical composition for treating fracture or bone split and its preparation method and application | |
| CN108126076A (en) | A kind of pharmaceutical composition for treating fracture or bone split and its preparation method and application | |
| CN103585414A (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN103735676B (en) | A kind of compound Chinese medicinal preparation for the treatment of traumatic injury and its preparation method and application | |
| CN107913374A (en) | A kind of pharmaceutical composition for treating calculus and preparation method thereof | |
| CN102370838B (en) | Kidney-invigorating and tendon-reinforcing double-phase capsule | |
| CN106581299A (en) | Traditional Chinese medicinal composition for improving kidney qi deficiency syndrome of people of middle aged and elderly people, and application thereof | |
| CN106822852A (en) | Treat pharmaceutical composition, its preparation technology and the purposes of coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180508 |